| pubmed-article:10577851 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C0054946 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C1417326 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C1706319 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C0085101 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C1519043 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:10577851 | lifeskim:mentions | umls-concept:C0879283 | lld:lifeskim |
| pubmed-article:10577851 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:10577851 | pubmed:dateCreated | 2000-1-28 | lld:pubmed |
| pubmed-article:10577851 | pubmed:abstractText | Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody targets CD20, a B-lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum-tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy. | lld:pubmed |
| pubmed-article:10577851 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10577851 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10577851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10577851 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10577851 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:10577851 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:JanakiramanNN | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:ParkerEE | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:WhiteC ACA | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:GordonL ILI | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:GutheilJJ | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:SpiesSS | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:Grillo-LópezA... | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:SchilderR JRJ | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:WitzigT ETE | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:RaubitschekAA | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:SilvermanD... | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:WisemanG AGA | lld:pubmed |
| pubmed-article:10577851 | pubmed:author | pubmed-author:Emmanouilides... | lld:pubmed |
| pubmed-article:10577851 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10577851 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:10577851 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10577851 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10577851 | pubmed:pagination | 3793-803 | lld:pubmed |
| pubmed-article:10577851 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:meshHeading | pubmed-meshheading:10577851... | lld:pubmed |
| pubmed-article:10577851 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10577851 | pubmed:articleTitle | Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:10577851 | pubmed:affiliation | Divisions of Hematology and Nuclear Medicine, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. | lld:pubmed |
| pubmed-article:10577851 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10577851 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10577851 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10577851 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:10577851 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:10577851 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10577851 | lld:pubmed |
